

Comment

# Comment on Guerrero-Romero et al. Magnesium-to-Calcium Ratio and Mortality from COVID-19. *Nutrients* 2022, 14, 1686

Giuliana Scarpati \*  and Ornella Piazza 

Surgery and Dentistry “Scuola Medica Salernitana”, Department of Medicine, University of Salerno, 84084 Baronissi, SA, Italy

\* Correspondence: gscarpati@unisa.it; Tel.: +39-3478543403

We read with great interest the article by Romero et al. “Magnesium-to-Calcium Ratio and Mortality from COVID-19” [1], which evaluated the association of the serum magnesium-to-calcium ratio with mortality in a cohort of 1064 COVID-19 patients. Magnesium supports the action of numerous anti-covid drugs [2] and the relevance of magnesium homeostasis for COVID-19 mortality has already been reported [3], while Romero et al., by comparing the data of 554 patients discharged per death with the data of 510 patients discharged per recovery, found that the best cut-off point for the magnesium-to-calcium ratio for identifying individuals at a high risk of mortality from COVID-19 was 0.20 (sensitivity 83%; specificity 24%). Nevertheless, ionized serum magnesium might be a better marker to identify critically ill patients with an impaired magnesium status, and accurately and routinely measuring ionized magnesium in critically ill patients may be helpful when replacing this micronutrient [4]. In our experience with 133 severe COVID-19 patients, who were admitted to ICU because of respiratory failure, we found that the Mg/Ca ratio was higher in the surviving patients than in the non-survivors ( $p < 0.001$ ) and that a Mg/Ca ratio  $< 0.3$  mg/dL was associated with a higher mortality (ROC curve Mg/Ca ratio: AUC = 0.565, J 0.24405, cut-off  $> 0.3$ ; Sensitivity 0.28; Specificity 0.95). Moreover, we explored the association between the ionized-magnesium/ionized-calcium (iMg/iCa) ratio and mortality in the same population. The iMg/iCa ratio was higher in the surviving patients (Figure 1) and an iMg/iCa ratio of less than 0.55 mmol/L was associated with a higher mortality in patients with severe COVID-19. The analysis of the ROC curve for the iMg/iCa ratio (AUC 0.972; J 0.90909, cut-off 0.55) revealed a very high sensitivity (0.90) and specificity (1.00).



**Citation:** Scarpati, G.; Piazza, O. Comment on Guerrero-Romero et al. Magnesium-to-Calcium Ratio and Mortality from COVID-19. *Nutrients* 2022, 14, 1686. *Nutrients* 2022, 14, 3442. <https://doi.org/10.3390/nu14163442>

Academic Editor: Roberto Iacone

Received: 1 July 2022


Accepted: 15 August 2022

Published: 22 August 2022

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).



**Figure 1.** Box Plot iMg/iCa ratio by outcome.

Interestingly, the serum magnesium and calcium values were within the normal range in all the 133 patients admitted to our COVID-19 ICU and no correlation between Mg and Ca serum levels and the well-known COVID-19-associated risk factors such as obesity, diabetes, or hypertension was found, nor was there a significant difference in the patients treated with invasive or non-invasive ventilation.

Although our outcomes are absolutely preliminary, if taken together with Romero's results, they encourage Mg/Ca ratio use as a potential biomarker for phenotyping patients according to their disease severity, or as a prognosis biomarker. Nevertheless, even if a Mg/Ca ratio < 0.3 mg/dL and an iMg/iCa ratio < 0.55 are associated with a higher mortality, unfortunately, we do not possess enough knowledge to answer to the following question: does the supplementation of magnesium offer a therapeutical opportunity for severe COVID-19 patients?

**Author Contributions:** Conceptualization, methodology, validation, writing—original draft preparation, G.S. and O.P.; All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Guerrero-Romero, F.; Mercado, M.; Rodríguez-Morán, M.; Ramírez-Rentería, C.; Martínez-Aguilar, G.; Marrero-Rodríguez, D.; Ferreira-Hermosillo, A.; Simental-Mendía, L.E.; Remba-Shapiro, I.; Gamboa-Gómez, C.I.; et al. Magnesium-to-Calcium Ratio and Mortality from COVID-19. *Nutrients* **2022**, *14*, 1686. [[CrossRef](#)]
2. Pagliano, P.; Sellitto, C.; Scarpati, G.; Ascione, T.; Conti, V.; Franci, G.; Piazza, O.; Filippelli, A. An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). *Expert Opin. Drug Discov.* **2022**, *17*, 9–18. [[CrossRef](#)] [[PubMed](#)]
3. Trapani, V.; Rosanoff, A.; Baniyadi, S.; Barbagallo, M.; Castiglioni, S.; Guerrero-Romero, F.; Iotti, S.; Mazur, A.; Micke, O.; Pourdowlat, G.; et al. The relevance of magnesium homeostasis in COVID-19. *Eur. J. Nutr.* **2022**, *61*, 625–636. [[CrossRef](#)] [[PubMed](#)]
4. Scarpati, G.; Baldassarre, D.; Oliva, F.; Pascale, G.; Piazza, O. Ionized or Total Magnesium levels, what should we measure in critical ill patients? *Transl. Med. UniSa* **2020**, *23*, 68–76. [[CrossRef](#)] [[PubMed](#)]